Reports on the investigations were presented at the Influenza Vaccines for the World Conference held in Valencia, Spain, and the Infectious Diseases Week Congress in San Diego, California, according to PharmAlive.com.
GSK’s candidate vaccines contain protection against two influenza A strains and two influenza B strains in order to potentially broaden the protection offered by traditional trivalent seasonal vaccines, which currently offer protection against two influenza A strains and one influenza B strain.
The company conducted four immunogenicity studies on the new QIVs in both children and adults. The vaccines were shown to be highly immunogenic against all of the strains contained in the vaccines. Both met the primary endpoint of non-inferiority for the common strains in all of the groups studied. Additionally, the vaccines met the superiority endpoint for the additional Influenza B strain, PharmAlive.com reports.
GSK also undertook a fifth study for efficacy in children aged three to eight years. In this study, the vaccine proved capable of offering protection against both mild and severe infections.
The QIVs are currently under development in two manufacturing facilities. One is located in Dresden, Germany, and the other in Quebec, Canada.